Identification of therapeutic target molecules againstatrial fibrillation: Use of the canine persistent atrial fibrillation model

首次建立慢性持续性心房颤动模型。将Beagle犬造成完全性房室传导阻滞，左心房植入起搏电极，右心房皮下植入电刺激发生装置。通过对心房进行电刺激（600 bpm）4周来诱导慢性持续性房颤。接下来，在该模型中评价了现有药物（匹西卡尼、丙吡胺、阿普林定、西苯唑啉）、I_Kur阻断剂（AVE 0118）和奥司他韦。很明显，奥司他韦比现有的抗房颤药物具有更强的抗心律失常作用。

The chronic persistent atrial fibrillation model was developedfirst. The complete atrioventricular block was produced to the beagle, the left atrium was equipped with the pacing electrode, and electric stimulus generating equipment was embedded at the right buttock subcutaneous part. Chronic persistent atrial fibrillation was induced by performing an electric stimulus (600 bpm) of an atrium for four weeks. Next, the existing drugs (pilsicainide, disopyramide, aprindine, cibenzoline), an I_Kurblocking agent (AVE0118), and oseltamivir were evaluated in this model. It became clear that oseltamivir has more potent antiarrhythmic effect than the existing anti-atrial fibrillation drugs.